PSNL
T2Personalis, Inc.
Biotech '26: AI Driven Drug DiscoveryGenomics '25: Molecular Diagnostics & Clinical GenomicsMedTech Long '25: Cancer Diagnostics, Platforms & CareMedTech Long '25: Diagnostic PlatformsMedTech Long '26: Diagnostics & Early Detection
OverviewPersonalis, Inc. is a cancer genomics company specializing in ultrasensitive liquid biopsies, primarily NeXT Personal, to detect cancer recurrence early. They a
Personalis, Inc. is a cancer genomics company specializing in ultrasensitive liquid biopsies, primarily NeXT Personal, to detect cancer recurrence early. They also provide precision oncology platforms for biopharmaceutical drug development. Revenue is transitioning to high-value clinical and biopharma MRD testing, which together generated $4.5 million in Q1 2026. They sell to biopharma, academic, non-profit, and government entities, and are being acquired by Tempus AI.
- What They Do (Plain English & Analogies)
- Personalis, Inc. acts like a highly skilled detective for cancer. They use incredibly sensitive blood tests to find tiny, invisible fragments of cancer DNA in a patient's blood, even if there's only one cancer fragment among a million normal ones. This allows doctors to detect if cancer is coming back (recurrence) much earlier than traditional methods like X-rays or scans, sometimes months or even years ahead. This level of precision is now considered a clinical necessity. Beyond helping individual patients, they also work with pharmaceutical companies, acting as the 'engine' behind the next generation of precision cancer treatments. They analyze tumors, help identify new disease markers, and ensure drug trials are effective. The company is in the process of being acquired by Tempus AI, which will integrate Personalis's advanced cancer tracking technology into Tempus's broader AI-driven platform.
- Very Brief History
- Founded in 2011 as a Stanford University spin-out, Personalis, Inc. has evolved into a specialized cancer genomics firm. A key milestone was the launch of their NeXT Personal platform, which became central to their 'win-in-MRD' (minimal residual disease) strategy. In a significant development, Tempus AI announced on July 20, 2026, its definitive agreement to acquire Personalis for approximately $1.5 billion, with the deal expected to close in late 2026 or early 2027, pending approvals.
- "Street Stereotype"
- Personalis is generally perceived as an emerging and innovative player in the rapidly growing molecular residual disease (MRD) market, particularly recognized for its ultrasensitive whole-genome liquid biopsy technology. The recent announcement of its acquisition by Tempus AI has solidified its stereotype as a valuable asset in the cancer monitoring space, poised for broader integration within an AI-driven precision medicine platform.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Personalis's customers are primarily in the biopharmaceutical sector, academic institutions, non-profit organizations, and government entities. Specific clients and partners mentioned include Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., Moores Cancer Center, and Moderna. Tempus is also a significant commercial partner, and now a pending acquirer.
- New Customers / Segments They'Re Targeting
- Personalis is squarely focused on driving volume in the large and rapidly expanding MRD market, targeting a broader base of ordering physicians, having surpassed 1,000 ordering physicians in Q1 2026. They are expanding into new cancer indications for reimbursement, including neoadjuvant breast cancer and pan-cancer immunotherapy monitoring, which are currently under review for coverage. The company is also expanding into additional cancer types, such as colorectal cancer, and continues to grow its biopharma MRD pipeline.
- Supply Chain And Sourcing Geographies
- The provided transcript and existing information do not offer specific details regarding Personalis's supply chain or the geographic sourcing of its products and components. The company's headquarters and primary laboratory operations are located in Fremont, California, USA. An older SEC filing mentions reliance on third-party supply chains but does not specify geographies.
- Sales Geographies And Expansion Plans
- Personalis primarily operates within the United States, focusing on U.S. Medicare reimbursement. The company has a European office in West Wickham, Kent, UK, and handles sales inquiries for North America, Europe, and the 'Rest of World'. Its commercial footprint is scaling within the U.S. through its partnership with Tempus. While the pending acquisition by Tempus AI may eventually lead to broader geographic reach through Tempus's existing global operations, Personalis, as a standalone entity, has not explicitly disclosed specific plans for international sales expansion beyond its current operational presence.
- How Key Themes May Help/Hurt
- Personalis is strongly positioned within the 'MedTech Long '26: Diagnostics & Early Detection' theme. The accelerating technological advancements in genomics and AI are directly driving the adoption of their ultrasensitive NeXT Personal platform, expanding its clinical utility and market opportunities. [cite: Theme_BullBearDetails] The increasing global prevalence of cancer and an aging population create a sustained demand for advanced diagnostic solutions like Personalis's early recurrence detection tests. [cite: Theme_BullBearDetails] Favorable regulatory developments, such as Medicare coverage pathways for novel diagnostic tests, are crucial for Personalis, as they actively pursue MolDX reimbursement for various cancer indications, which enhances market access and accelerates commercialization. [cite: 1, Theme_BullBearDetails] The pending acquisition by Tempus AI, an AI-powered precision diagnostics platform, further integrates Personalis into the AI-driven precision medicine trend. [cite: CONSTITUENT MEMBERSHIP NOTES] However, Personalis is hurt by persistent reimbursement pressures and evolving payer policies, which contribute to gross margin compression due to unreimbursed tests. [cite: 1, Theme_BullBearDetails] Additionally, the intensifying competition from both established players and new entrants in the diagnostics and early detection space could lead to pricing pressures and increased commercialization costs, impacting Personalis's margins. [cite: 1, Theme_BullBearDetails]
3 Main Long-Term Bull Details
- Industry-Leading Ultrasensitive MRD Technology: Personalis's NeXT Personal platform offers superior ultrasensitivity, detecting cancer recurrence months and years ahead of standard imaging, with 40% of positive signals occurring in the ultrasensitive range across 14 cancer types. This precision is a clinical necessity, driving competitive wins and high physician retention (over 98% in Q1 2026).
- Accelerating Clinical Adoption and Robust Biopharma Pipeline: The company is demonstrating significant clinical volume growth, with over 7,800 clinical tests delivered in Q1 2026 (26% sequential, 258% year-over-year growth), surpassing 1,000 ordering physicians. The biopharma MRD pipeline is also robust, with a full-year 2026 revenue goal of $20 million to $21 million, largely realized in the second half.
- Strategic Acquisition by Tempus AI: The pending acquisition by Tempus AI for approximately $1.5 billion provides Personalis with significant scale, resources, and AI capabilities, accelerating the innovation and adoption of its NeXT Personal platform within a broader precision medicine ecosystem.
3 Main Long-Term Bear Details
- Persistent Gross Margin Pressure and High Cash Burn: Gross margins remain under significant pressure due to strategic investments in market share and unreimbursed tests, with Q1 2026 gross margin at 1.8%. This margin compression is expected to continue through the first half of 2026. The company also experiences a high cash burn and net losses, with Q1 2026 net loss of $30.0 million and anticipated full-year cash usage of approximately $100 million.
- Reimbursement Timing and Variability: The timing and variability of MolDX reimbursement decisions for new indications, such as pan-cancer immunotherapy and neoadjuvant breast cancer, pose a risk. Delays in securing broader coverage could prolong the period of margin dilution and high cash burn, impacting the pace of market access and the conversion of high test volumes into higher-margin revenue.
- Intense Competitive Landscape: The molecular residual disease (MRD) market is highly competitive, with strong players like Natera and Exact Sciences. While Personalis differentiates with ultrasensitivity, continuous innovation and robust clinical evidence are required to maintain its competitive edge against both established players and new entrants, including those with tumor-naïve approaches.
- Competitors And Differentiation
- Personalis operates in a competitive market, with implied competitors including Guardant Health (with its tumor-naïve Reveal test) and other strong players in the molecular residual disease (MRD) market. Personalis differentiates itself through its industry-leading ultrasensitivity and tumor-informed approach, which allows for the detection of a single fragment of tumor DNA in a background of a million. This precision enables oncologists to detect cancer recurrence months and years ahead of standard imaging, with 40% of positive detections occurring in the ultrasensitive range (below 100 parts per million) across 14 different cancer types, signals that conventional tests often miss. They believe this ultrasensitive, tumor-informed approach will 'carry the day' in terms of sensitivity, which is what most physicians demand.
- Recent Performance & What The Market'S Focused On
- In Q1 2026, Personalis reported total revenue of $15.5 million, a 25% decrease year-over-year, reflecting a planned transition away from lower-margin legacy revenue. However, clinical test volumes showed strong growth, reaching over 7,800 tests, representing a 26% sequential increase and a 258% year-over-year surge, with over 1,000 ordering physicians. Strategic revenue (clinical testing and biopharma MRD adoption) was $4.5 million, with biopharma MRD revenue at $3.1 million. Gross margin remained low at 1.8% due to investments in market share and unreimbursed tests, leading to a net loss of $30.0 million and cash usage of $28 million. The company secured Medicare coverage for breast cancer in November 2025 and lung cancer in February 2026, and submitted neoadjuvant breast cancer and pan-cancer immunotherapy for coverage review. The market is primarily focused on Personalis's ability to scale its NeXT Personal clinical test volumes to meet the full-year 2026 target of 43,000-45,000 tests, the timing and expansion of MolDX reimbursement for new indications (especially pan-cancer immunotherapy and neoadjuvant breast cancer) to drive gross margin improvement in the second half of 2026, and the anticipated significant ramp-up of biopharma MRD revenue in the latter half of the year. The pending acquisition by Tempus AI for $1.5 billion is also a key focus, with investors watching for its successful closing and the integration's impact on Personalis's growth trajectory.
- Revenue Segments And Estimated Mix
- Total Company Revenue — Mix: $15.5 million; Source: Q1 2026 transcript; Trend: 25% lower than a year ago due to planned transition and Moderna decrease; full-year 2026 guidance: $78M-$80M
- Strategic Revenue (Clinical Testing & Biopharma MRD Adoption) — Mix: $4.5 million; Source: Q1 2026 transcript; Trend: Expected to more than double year over year to $30M-$32M for full year 2026
- Biopharma Testing Services — Mix: $11.2 million; Source: Q1 2026 transcript; Trend: Decline due to expected decrease from Moderna; Biopharma MRD revenue was $3.1M in Q1, expected to be $20M-$21M for full year 2026
- Clinical Revenue — Mix: $1.4 million; Source: Q1 2026 transcript; Trend: Up from $300,000 in Q1 2025 due to Medicare coverage for breast and lung cancer surveillance; expected to be $10M-$11M for full year 2026
- Population Sequencing plus Enterprise Customers — Mix: approximately $13 million; Source: Full-year 2026 guidance; Trend: n/m
- Product Brands
- NeXT Platform
- ImmunoID NeXT
- NeXT Liquid Biopsy
- NeXT Personal
- NeXT Dx Test
- NeXT SHERPA
- NeXT NEOPS
- ACE platform
- Variant Tracker
Bull / Bear DetailsPersonalis, Inc. offers a compelling long opportunity as its ultrasensitive NeXT Personal platform continues to disrupt the $20B+ MRD market, driving significan
Thesis
Personalis, Inc. offers a compelling long opportunity as its ultrasensitive NeXT Personal platform continues to disrupt the $20B+ MRD market, driving significant clinical volume and biopharma adoption. Confirmed Medicare coverage for IO monitoring and neoadjuvant breast cancer, alongside existing breast and lung coverage, strengthens its reimbursement trajectory. The pending Tempus AI acquisition further solidifies its market position. While near-term gross margin compression and high cash burn persist, expanding coverage and a robust pipeline position PSNL for long-term leadership. (Updated: 2026-08-06)
Bull case
Personalis' NeXT Personal platform demonstrates industry-leading ultrasensitivity, detecting cancer recurrence months and years ahead of standard imaging. Q1 2026 clinical test volumes of 7,800 represent 26% sequential and 258% year-over-year growth. Recent AACR data showed 100% negative predictive value for CRC relapse and 40% of positive detections in the ultrasensitive range across 14 cancer types, validating its clinical necessity.
The company is achieving strong clinical adoption, surpassing 1,000 ordering physicians in Q1 2026 with over 98% retention, and is on track for 43,000-45,000 annual clinical tests in 2026. The biopharma MRD pipeline is robust, with Q1 2026 revenue of $3.1 million and a full-year goal of $20 million to $21 million, expected to accelerate significantly in the second half as large trials commence.
Medicare coverage for pan-cancer immunotherapy monitoring (May 13, 2026) and neoadjuvant breast cancer (May 20, 2026) has been secured, significantly expanding reimbursed indications beyond existing breast and lung cancer surveillance. This, coupled with the pending acquisition by Tempus AI for approximately $1.5 billion, provides Personalis with enhanced scale, resources, and AI capabilities to accelerate market penetration.
Bear case
Gross margins remain under significant pressure due to strategic investments and unreimbursed tests. Q1 2026 gross margin was 1.8%, a substantial decrease from 35% in the prior year, with unreimbursed tests diluting margins by over 2,000 basis points. This margin compression is expected to continue through the first half of 2026, impacting profitability, with improvement anticipated in the second half.
The company continues to experience a high cash burn and net losses, with a Q1 2026 net loss of $30.0 million and cash usage of approximately $28 million. Personalis anticipates full-year 2026 cash usage to be around $100 million. Despite $233.2 million in cash, sustained high burn rates necessitate efficient execution and rapid conversion of reimbursed volume to revenue to ensure long-term liquidity.
The competitive landscape in the molecular residual disease (MRD) market is intense, with strong players and the growth of tumor-naïve tests. While Personalis differentiates with ultrasensitivity, maintaining a competitive edge requires continuous innovation and robust clinical evidence. Furthermore, the closing of the Tempus AI acquisition, while positive, still faces regulatory clearances and shareholder approval, introducing potential for delays or unforeseen conditions.
Bull / Bear Case
- Bear Case
- Despite growth, Personalis faces significant gross margin pressure, with Q1 2026 at a low 1.8%, diluted by over 2,000 basis points from unreimbursed tests. This margin compression is expected to persist through H1 2026. The company continues to experience high cash burn and net losses ($30.0M net loss in Q1 2026, $100M anticipated full-year cash usage), necessitating efficient execution. The molecular residual disease (MRD) market is intensely competitive, requiring continuous innovation to maintain an edge against both tumor-informed and tumor-naïve approaches. Furthermore, the announced Tempus AI acquisition, while strategic, still requires regulatory clearances and shareholder approval, introducing potential for delays or unforeseen conditions that could impact the deal's completion or terms.
- Bull Case
- Personalis's NeXT Personal platform demonstrates industry-leading ultrasensitivity, disrupting the $20B+ MRD market by detecting cancer recurrence months and years ahead of standard imaging. Q1 2026 saw robust clinical test volume growth (7,800 tests, 26% sequential, 258% YOY) and strong physician adoption (>1,000 ordering physicians, >98% retention). The biopharma MRD pipeline is robust, targeting $20M-$21M in 2026, with significant acceleration expected in H2. Recent Medicare coverage for pan-cancer immunotherapy monitoring and neoadjuvant breast cancer further expands reimbursed indications. The pending acquisition by Tempus AI for approximately $1.5 billion provides enhanced scale, resources, and AI capabilities, solidifying its market position and accelerating innovation.
- More Compelling & Why
- Bull. Given the pending acquisition by Tempus AI for approximately $1.5 billion, the primary valuation metric is the current stock price relative to the implied acquisition value. Assuming the stock is trading at a slight discount to this value, the most compelling argument is the high probability of the acquisition closing, offering a near-term arbitrage opportunity. My view would flip to Bear if significant regulatory hurdles or shareholder dissent emerge, or if the stock price trades above the implied acquisition value, indicating an overvaluation relative to the deal terms.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| NeXT Personal Clinical Test Volume | This metric directly reflects the success of Personalis' 'win-in-MRD' strategy and market share gains for NeXT Personal, a key driver for future revenue and reimbursement. Continued growth indicates strong adoption and market penetration. | Q2 2026 clinical test volume. The full-year 2026 target is 43,000-45,000 tests. The rerating threshold for Q2 2026 was exceeding 10,000 tests, representing a sequential growth rate of at least 30% over Q1 2026's 7,800 tests. | Bullish: Q2 2026 volume exceeding 10,000 tests (actual was 10,384 tests) and maintaining momentum towards the full-year target. | Company earnings reports (next would be Q2 2026 earnings, typically released in early August). | Thinknum: Sales volume data for diagnostic tests | |
| Gross Margin Performance | Gross margin is crucial for profitability, as current margins are diluted by unreimbursed tests. Improvement is expected in the second half of 2026 with expanded reimbursement coverage, particularly for IO, signaling a path to financial health. | Q2 2026 gross margin. Management guided for Q1/Q2 to be the lowest point, with improvement in H2 2026. The rerating threshold for Q2 2026 was ideally exceeding 5%. | Bullish: A Q2 2026 gross margin exceeding 5% or clear sequential improvement from Q1 2026's 1.8% would validate the strategy and signal improving profitability. | Company earnings reports (next would be Q2 2026 earnings, typically released in early August). | ||
| Biopharma MRD Revenue Growth | This high-value, high-margin segment is expected to accelerate significantly in the second half of 2026, demonstrating adoption of Personalis' ultrasensitive technology by biopharma companies for next-gen therapies. | Q2 2026 biopharma MRD revenue. The full-year 2026 goal is $20 million to $21 million, with the majority expected in H2. The rerating threshold for Q2 2026 was at least $5 million. | Bullish: Q2 2026 biopharma MRD revenue of at least $5 million, indicating the anticipated acceleration is on track. | Company earnings reports (next would be Q2 2026 earnings, typically released in early August). | Earnest Analytics: Biopharma contract awards | |
| MolDX Reimbursement for IO Monitoring and Neoadjuvant Breast Cancer | Securing Medicare coverage for these indications significantly expands the addressable market for NeXT Personal, driving higher-margin revenue and validating the clinical utility of the test. | Confirmation of Medicare coverage for pan-cancer immunotherapy monitoring (late-stage solid tumors) and Neoadjuvant Breast Cancer (Stage II-III TNBC or HER2+ breast cancer). | Bullish: MolDX granted coverage for both pan-cancer immunotherapy monitoring (May 13, 2026) and neoadjuvant breast cancer (May 20, 2026), validating clinical utility and expanding market access. | Company press releases, SEC filings, MolDX website. | CMS website for MolDX updates | |
| Tempus AI Acquisition Closing Milestones | The pending acquisition by Tempus AI provides Personalis with significant scale, resources, and AI capabilities, accelerating the innovation and adoption of its NeXT Personal platform. | Personalis shareholder approval, regulatory clearances (e.g., HSR Act, anti-trust reviews). The definitive agreement was announced on July 20, 2026, with closing expected in late 2026 or early 2027. | Bullish: Shareholder approval and regulatory clearances obtained without significant delays or conditions. | SEC filings (e.g., proxy statements, 8-K filings), company press releases. |
Key Reported Metrics, Reratings Triggers & ResultsThis metric is crucial as it reflects the direct impact of Medicare reimbursement coverages for breast, lung, IO monitoring, and neoadjuvant breast cancer, sign
Last reported · 2026-08-04
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Clinical Revenue | 442% | This metric is crucial as it reflects the direct impact of Medicare reimbursement coverages for breast, lung, IO monitoring, and neoadjuvant breast cancer, signaling progress towards higher-margin revenue and financial health. | For the Q2 2026 earnings report, Personalis, Inc.'s Clinical Revenue needed to hit at least $2.5 million. This would represent a sequential growth of over 78% from Q1 2026's $1.4 million, and a substantial year-over-year increase, demonstrating the positive impact of new Medicare coverage for IO monitoring and neoadjuvant breast cancer, which was secured in May 2026. | Achieving this threshold would validate Personalis' 'win-in-MRD' strategy and the successful monetization of its ultrasensitive NeXT Personal platform. It would signal clear progress towards higher-margin revenue and improved financial health, reinforcing the strategic value of the company and its market position, especially in light of the pending Tempus AI acquisition. | |
| Pharma Testing Services and All Other Customers Revenue | 51% | This segment includes Biopharma MRD revenue, a high-value, high-margin area expected to accelerate significantly. Its growth demonstrates adoption of Personalis' ultrasensitive technology by biopharma companies for next-gen therapies. | Personalis, Inc. (PSNL) needs to report Biopharma MRD Revenue of at least $5 million for the upcoming Q2 2026 earnings report. | Achieving at least $5 million in Q2 Biopharma MRD Revenue would validate Personalis' 'win-in-MRD' strategy and the anticipated acceleration in this high-value segment. This performance would reinforce the strategic rationale for the pending Tempus AI acquisition, demonstrating the underlying strength of the acquired asset and increasing confidence in the deal's successful completion. | |
| NeXT Personal Clinical Test Volume | 199% | This metric directly reflects the success of Personalis' 'win-in-MRD' strategy and market share gains for NeXT Personal, a key driver for future revenue and reimbursement. Continued growth indicates strong adoption and market penetration. | Clinical test volume exceeding 10,000 tests, representing a sequential growth rate of at least 30% over Q1 2026's 7,800 tests. | Achieving this accelerated clinical test volume growth validates Personalis' 'win-in-MRD' strategy and NeXT Personal adoption. Strong growth signals increasing market penetration, driving future revenue, expanded reimbursement, improved gross margins, and reduced cash burn, supporting a positive rerating. | |
Key QuestionsWill Personalis sustain its strong sequential growth in NeXT Personal clinical test volumes beyond Q2 2026, and will biopharma MRD revenue achieve its anticipat
Will Personalis sustain its strong sequential growth in NeXT Personal clinical test volumes beyond Q2 2026, and will biopharma MRD revenue achieve its anticipated significant ramp-up in the second half of the year to meet full-year 2026 guidance?
- Question 2
Following the MolDX coverage decisions for pan-cancer immunotherapy monitoring and neoadjuvant breast cancer in Q2 2026, will these approvals translate into the anticipated gross margin improvement in the second half of the year, and how quickly will they drive higher reimbursed revenue?
- Question 3
Given the announcement of the definitive agreement for Tempus AI to acquire Personalis, will the acquisition proceed as expected with shareholder and regulatory approvals, and how will this impact Personalis's operational focus and financial trajectory, including cash burn, over the next quarter leading up to the anticipated late 2026/early 2027 closing?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Driving volume and scaling NeXT Personal in the MRD market: Management highlighted a 258% year-over-year increase in clinical tests, exceeding 1,000 ordering physicians, and maintaining the 2026 annual volume estimate of 43,000-45,000 tests. 2. Building clinical evidence to secure and expand reimbursement: This includes submissions for neoadjuvant breast cancer and pan-cancer immunotherapy monitoring, supported by strong data presented at AACR, with expectations for improved gross margins in the second half of the year. 3. Leadership in the biopharma sector and growing the biopharma MRD pipeline: Management is focused on accelerating biopharma MRD revenue, expecting significant scaling in the second half of the year, with a full-year goal of $20 million to $21 million, driven by their ultrasensitive technology. | The call conveyed a cautiously optimistic tone, with management expressing strong confidence in their 'win-in-MRD' strategy. Key takeaways included significant clinical volume growth (258% y/y), progress in securing Medicare reimbursement for breast and lung cancer, and a robust biopharma MRD pipeline expected to accelerate in the second half of 2026. Management acknowledged temporary gross margin compression due to strategic investments in market share and unreimbursed tests but projected improvement in the latter half of the year. The overall focus remains on scaling NeXT Personal, expanding clinical evidence, and growing the biopharma MRD pipeline, despite a planned decline in legacy revenue streams. | Total company revenue (Q4 2025): +3% y/y. Biopharma testing services (Q4 2025, approximated from 'Pharma testing services and all other customers'): -34.34% y/y. Clinical revenue (Q4 2025): +350% y/y. | 1. Competitive wins and the effectiveness of their strategy: Analysts questioned what Personalis observed in Q1 to confirm their strategy was effective. Management responded by citing 26% sequential volume growth, over 1,000 ordering physicians with 98% retention, and the competitive advantage of their ultrasensitive capability. 2. Gross margin trajectory and sales team incentives for reimbursed indications: Analysts inquired about Q2 gross margin expectations and whether the sales team was incentivized to promote reimbursed indications. Management explained that Q2 margins would remain low but anticipated improvement in H2 with increasing reimbursed clinical and biopharma MRD revenue, stating they do not disincentivize non-paid tests to build evidence for future reimbursement. 3. The ultrasensitive, tumor-informed approach versus tumor-naïve tests: Analysts asked about the market's interest in the ultrasensitive approach compared to first-generation or tumor-naïve tests. Management affirmed their belief that the tumor-informed approach, due to its superior sensitivity, is a 'clinical necessity' and will be the preferred method, gaining increasing recognition at medical conferences. | Total company revenue: -25% y/y. Biopharma testing services: -17.65% y/y (Q1 2026 revenue of $11.2 million vs. $13.6 million in Q1 2025). Clinical revenue: +366.67% y/y (Q1 2026 revenue of $1.4 million vs. $300,000 in Q1 2025). Strategic revenue (clinical testing and biopharma MRD adoption) was $4.5 million in Q1 2026, with full-year 2026 strategic revenue expected to more than double year over year to a range of $30 million to $32 million. Biopharma MRD revenue was $3.1 million in Q1 2026, with a full-year goal of $20 million to $21 million. Population sequencing plus enterprise customers are expected to be approximately $13 million for the full year 2026. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| The clinical market for tracking cancer in the blood, or MRD, is advancing toward a $20+ billion opportunity, and Personalis, Inc. is armed with the right technology to win. The company submitted neoadjuvant breast cancer and pan-cancer immunotherapy monitoring for coverage review, expanding potential reimbursed indications. Personalis is scaling its commercial footprint with partner Tempus, targeting 43,000 to 45,000 annual clinical tests in 2026. The biopharma MRD pipeline is growing robustly, with a revenue goal of $20 million to $21 million this year, as biopharma companies adopt NeXT Personal for next-gen therapies due to its ultrasensitivity. The market is expanding rapidly and is expected to grow to $20 billion or more. | Personalis believes its ultrasensitive, tumor-informed approach will 'carry the day' in terms of sensitivity, which is what most physicians demand, in contrast to tumor-naïve tests. The company is winning in the marketplace due to its ultrasensitive capability. Its NeXT Personal platform has 'disrupted the market' since its launch. Biopharma companies recognize the need for the highest-resolution tools available to prove the efficacy of next-gen therapies, driving adoption of NeXT Personal. | The first quarter is typically the industry's most challenging due to standard seasonality. There is increasing recognition that ultrasensitivity is critical for patients in MRD testing, evolving from a 'nice-to-have' to a 'must-have'. | Personalis is focused on driving volume in the large and rapidly expanding MRD market, aiming to scale its platform in 2026 after establishing its power in 2025. The company remains on track to achieve its full-year revenue guidance of $78 million to $80 million, with strategic revenue expected to more than double year over year. The majority of biopharma MRD revenue is expected in the second half of 2026 as larger projects ramp up. Gross margin dilution is expected to continue through 2026, with improvement anticipated when reimbursement coverage for IO is received, and benefits from market share investments are expected over the next two to three years. The company expects reimbursement to continue catching up in 2027 and beyond, leading to higher ASPs and reduced cash usage. | Diagnostics | I am incredibly proud of what our team has accomplished in this first quarter, and more importantly, I am energized by where we are going. Since we launched NeXT Personal, we have not just validated our win-in-MRD strategy; we have disrupted the market. This level of ultrasensitivity is no longer just a technical leap forward; it is a clinical necessity. The clinical market for tracking cancer in the blood, or MRD, is advancing toward a $20+ billion opportunity, and Personalis, Inc. is armed with the right technology to win. We delivered more than 7,800 clinical tests. This represents a 26% sequential growth over the fourth quarter, and a 258% year-over-year increase. We have now surpassed 1,000 ordering physicians in the quarter, and we are seeing incredible retention of over 98% over the past several quarters. Our biopharma MRD pipeline is growing robustly. We are leading the ultrasensitive MRD market with our technology, and the proof point is our ramping clinical test volume. | Total company revenue was $15.5 million for Q1 2026. On the surface, this amount is 25% lower than a year ago. Gross margin was 1.8% in the first quarter, compared with 35% for the same period of the prior year. We foresee this margin dilution to continue throughout 2026, with the lowest point expected to be in the first two quarters of the year. In the first quarter, unreimbursed test cost diluted margins by more than 2,000 basis points. Operating expenses were $32.4 million in the first quarter compared to $24.9 million for the same period of the prior year. Net loss for the first quarter was $30.0 million compared with $15.8 million for the same period of the prior year. We used approximately $28 million of cash in the first quarter. We expect our cash usage to be approximately $100 million as we continue to invest in our win-in-MRD strategy. | Personalis is investing in commercial resources to drive volume and is building its internal salesforce side-by-side with its partner Tempus to build capability. Some internal team members also assist Tempus representatives from a marketing perspective. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| The clinical market for tracking cancer in the blood, or MRD, is advancing toward a $20+ billion opportunity, and Personalis, Inc. is squarely focused on driving volume in this large and rapidly expanding market. The company has surpassed 1,000 ordering physicians in the quarter and is confident in its 2026 annual volume estimate of 43,000 to 45,000 tests. Personalis submitted neoadjuvant breast cancer and pan-cancer immunotherapy monitoring for coverage review, and its biopharma MRD pipeline is growing robustly, on track to achieve $20 million to $21 million in MRD revenue this year. The company also plans to expand into additional cancer types, including colorectal, with data to be presented at ASCO. Personalis is scaling its commercial footprint with partner Tempus and is investing in commercial resources to drive volume. | Personalis believes its ultrasensitive, tumor-informed approach will 'carry the day' in terms of sensitivity, which is what most physicians demand, in contrast to tumor-naïve tests. The company is winning in the marketplace due to its ultrasensitive capability and has 'disrupted the market' since the launch of its NeXT Personal platform. Biopharma companies are adopting NeXT Personal because they recognize the need for the 'highest-resolution tools available' to prove the efficacy of next-gen therapies. While Guardant disclosed that Reveal is a rapidly growing product on the tumor-naïve side, Personalis maintains that the tumor-informed approach will remain dominant due to its superior sensitivity. | The first quarter is typically the industry's most challenging due to standard seasonality. There is increasing recognition that ultrasensitivity is 'critical for patients' in MRD testing, evolving from a 'nice-to-have' to a 'must-have'. The market for using blood tests to better monitor cancer progression is continuing to grow, with a lot of energy and excitement. | Personalis is focused on driving volume in the large and rapidly expanding MRD market, aiming to scale its platform in 2026. The company remains on track for its full-year revenue guidance of $78 million to $80 million, with strategic revenue expected to more than double year over year. The majority of biopharma MRD revenue is expected in the second half of 2026 as larger projects ramp up. Gross margin dilution is expected to continue through the first two quarters of 2026, with improvement anticipated when reimbursement coverage for IO is received. Benefits from market share investments are expected over the next two to three years, with reimbursement continuing to catch up in 2027 and beyond, leading to higher ASPs and reduced cash usage. The company expects its cash usage to be approximately $100 million for the full year. Personalis plans to present more colorectal data and expand into additional cancer types at the upcoming ASCO conference. | Diagnostics | AI Driven Drug Discovery, Molecular Diagnostics & Clinical Genomics, Diagnostic Platforms | I am incredibly proud of what our team has accomplished in this first quarter, and more importantly, I am energized by where we are going. Since we launched NeXT Personal, we have not just validated our win-in-MRD strategy; we have disrupted the market. This level of ultrasensitivity is no longer just a technical leap forward; it is a clinical necessity. The clinical market for tracking cancer in the blood, or MRD, is advancing toward a $20+ billion opportunity, and Personalis, Inc. is armed with the right technology to win. We delivered more than 7,800 clinical tests. This represents a 26% sequential growth over the fourth quarter, and a 258% year-over-year increase. We have now surpassed 1,000 ordering physicians in the quarter, and we are seeing incredible retention of over 98% over the past several quarters. Our biopharma MRD pipeline is growing robustly. We are leading the ultrasensitive MRD market with our technology, and the proof point is our ramping clinical test volume. | Total company revenue was $15.5 million for Q1 2026. On the surface, this amount is 25% lower than a year ago. Gross margin was 1.8% in the first quarter, compared with 35% for the same period of the prior year. We foresee this margin dilution to continue throughout 2026, with the lowest point expected to be in the first two quarters of the year. In the first quarter, unreimbursed test cost diluted margins by more than 2,000 basis points. Operating expenses were $32.4 million in the first quarter compared to $24.9 million for the same period of the prior year. Net loss for the first quarter was $30.0 million compared with $15.8 million for the same period of the prior year. We used approximately $28 million of cash in the first quarter. We expect our cash usage to be approximately $100 million as we continue to invest in our win-in-MRD strategy. | Personalis is investing in commercial resources to drive volume, which implies an expansion of their sales force. The company is building capability side-by-side with its partner Tempus, and explicitly mentions applying resources with 'our own sales reps' to achieve its aggressive annual clinical test volume targets. |